Introduction
Epilepsy is a chronic neurological disorder that requires long term treatment. Various studies have demonstrated the role of oxidative stress in the pathogenesis of atherosclerosis, psychiatric and neurodegenerative disorders. [1] [2] [3] The brain is generally in a balanced redox state between oxidative and reactive conditions. However, reactive oxygen species have damaging effects when they are produced in excessive amounts and are unable to be eliminated by endogenous antioxidants. The brain remains particularly vulnerable to oxidative stress because of its high demand for oxygen. The oxygen is needed because the brain derives energy from oxidative phosphorylation in mitochondrial respiratory chains. [4] [5] [6] A disproportionate production of free radicals compared to antioxidant levels is thought to be an important contributory factor to the pathogenesis of several diseases by oxidative injury. Free radicals can also exacerbate some forms of seizure. The end products of lipid peroxidation, protein carbonyl groups and nitric oxide have been the most studied markers of oxidative damage. Animal studies as seizure models have provided evidence of increased oxidative stress (increased lipid peroxidation and protein carbonylation) following seizures. [7] [8] [9] However, the role of nitric oxide is still debatable. Some studies have shown increased levels of nitric oxide in patients, 13 while other studies have demonstrated that nitric oxide has a beneficial role as an anticonvulsant 11, 12 or have had inconclusive results. 10 AEDs may also modulate oxidative stress in epileptic patients. 14 Animal studies (in which antioxidants were used in addition to anticonvulsants) showed decreased oxidative stress and reduced frequency of seizures. 6, 15, 16 The complex mechanism of epileptogenesis remains largely unclear. However, neuronal death is one of the important events, and factors altering or influencing this event may play an important role. Oxidative stress by free radical generation does indeed play a role in mitochondrial dysfunction and cell death. The aim of this study is to determine the effects of epilepsy on nitric oxide levels, lipid peroxidation and protein carbonylation levels in patients with epilepsy and a healthy control group. The Purpose: Oxidative stress has been implicated in many pathological processes. The brain is highly susceptible to oxidative stress because of its high lipid content. In this study, the oxidative parameters in patients with epilepsy and those of a control group were measured. The study's aim was to determine whether there are differences between the oxidative levels of treated and untreated patients and whether there are differences between individual antiepileptic drugs. Methods: Oxidative parameters such as Malondialdehyde (MDA), Protein Carbonylation (PC) and Nitric Oxide (NO) levels were evaluated in 100 patients with epilepsy and compared to an equal number of age and sex matched healthy subjects. In the study group, the oxidative parameters of 25 untreated patients were compared to treated patients and the control group. The treated patients were divided into 2 groups based on their antiepileptic drugs (AEDs). Group 1 consisted of patients on a single AED, and group 2 was composed of patients taking more than one AED. A comparative study was performed on the oxidative parameters of medicated patients on single drug regimens and multidrug regimens. Results: The MDA and PC levels were significantly higher in patients than in the control group (P < 0.0001). However, there was no significant difference in the NO levels of patients and those of the control group. The 25 untreated patients had higher MDA and PC levels compared to both the control group (P < 0.0001) and treated patients (P < 0.0001). There was no difference in the oxidative levels between untreated patients and treated patients, group 1 and group 2, and individual AEDs.
Conclusions:
In this study, we demonstrated the presence of significantly increased levels of oxidative markers in patients with epilepsy as compared to the control group. AEDs did not influence the oxidative markers, suggesting the presence of seizure-induced oxidative stress.
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study also intends to assess the oxidative stress in patients with epilepsy who are not taking antiepileptic drugs and the effects of AEDs, if any, in patients receiving monodrug or multidrug therapy.
Materials and methods
The study was composed of 100 patients with epilepsy who were diagnosed with idiopathic generalised epilepsy on antiepileptic therapy. One hundred age and sex matched healthy volunteers served as the control group.
Patients included in the study had been seizure free for more than 3 days. All patients underwent a detailed examination which included demographics, seizure frequency, duration of illness and treatment. Patients with chronic medical illnesses such as hypertension, diabetes, rheumatoid arthritis, collagen vascular disease, chronic neurological illness or localisation related epilepsy; those who were smokers, alcoholics, tobacco chewers; and those taking any other medications were excluded from the study. EEG was performed in all patients, and several patients underwent neuroimaging for definitive diagnoses.
Five millilitres of venous blood was collected after an overnight fast, and 2 ml was transferred to EDTA-coated vacutainers for haemoglobin estimation. The remaining blood was transferred to clot activator coated vacutainers, allowed to clot and centrifuged for 5 min at 3000 rpm to obtain serum that was stored at À20 8C for further analysis. The serum samples were used to analyse routine biochemical investigation and oxidative biomarkers. The oxidative parameters tested were lipid peroxidation, protein carbonylation and nitric oxide levels. Lipid peroxidation was estimated by measuring the Malondialdehyde levels using a UV-visible spectrophotometer. 17 We used the TBARS Assay (thiobarbituric acid reactive substances assay) to determine the Malondialdehyde (MDA) levels, the end product of lipid peroxidation. 18 Protein carbonylation (PC) was estimated with the Resnic and Packer method. 19 We measured the oxidation of the protein by adding carbonyl groups to the spectrophotometric assay using 2,4-DNPH (2,4-dinitrophenylhydrazine) for detecting carbonyls. 20 Carbonylated plasma protein reacts with 2,4-DNPH, and the complex was measured at 360 nm. 21 Nitric oxide (NO) levels were determined using the Griess reagent in which NO reacts with 1% sulphanilamide in 5% phosphoric acid, and 10% naphthalene ethylenediamine dihydrochloride forming chromospheres, which can be read at 543 nm. 22 The oxidative levels were compared between patients and the control group. The 25 patients who were not on AEDs were compared with both patients on AEDs and the control group to eliminate the effects of the antiepileptic drugs. Depending upon treatment, the patients were divided into group 1 or group 2, composed of Monotherapy and Polytherapy recipients, respectively. Those patients on Monotherapy were treated with one of the following antiepileptic drugs: Carbamazepine, Phenytoin, Valproate, Clobazam, Phenobarbital, Lamotrigine, Topiramate or Levetiracetam. Group 2 was composed of patients on more than one drug (Polytherapy). The oxidative parameters were compared among patients on Monotherapy. All patients provided written informed consent. The study was approved by the Institutional Ethics Committee.
Statistical analysis
The data were analysed with the statistical package SPSS for Windows, version 11.5. Descriptive analyses are expressed as mean AE S.D. Paired t-tests were performed between patients and controls, before treatment and controls, and before and after treatment. One way analysis of variance (ANOVA) was used to estimate the differences between the study groups. Correlation coefficients were determined by Pearson's correlation test. P < 0.05 was considered to be statistically significant.
Results
The study included 100 patients with epilepsy (56 males, 44 females) and 100 control subjects (52 males, 47 females). The mean ages of the patients and control group were 26 AE 10 and 26 AE 8 years, respectively. The mean duration of illness in the patients was 7 AE 6 yrs. Twenty-five per cent of the patients were not on treatment, 66% were on monotherapy (Carbamazepine 16%, Phenytoin 20%, Valproate 17%, others 13%), and 34% were on Polytherapy. The demographics and epilepsy profiles are shown in Table 1 . The biochemical and oxidative parameters are shown in Table 2 . The total cholesterol, LDL and alkaline phosphatase levels were higher in patients than in the control group with a significant p value ( Table 2 ). The remainder of the biochemical parameters were normal.
In the entire group, the MDA levels in patients (6.80 AE 2.84 mmol/ml) were higher than those in the control group (1.64 AE 0.82 mmol/ml) with a significant P < 0.001 (Graph 1). The PC levels (0.71 AE 0.19 mg of protein/ml) in patients were higher than those of the controls (0.46 AE 0.16 mg of protein/ml) with a significant P < 0.001 (Graph 2). However, the NO levels were not significantly different between the patients (50.41 AE 18.29) and control group (51.95 AE 9.56) (P = 0.45) (Graph 3). The mean ages of untreated patients and control group were 24.76 AE 9.96 and 25.72 AE 7.77, respectively. Twenty-five patients were not on AEDs. Hence, it was possible to evaluate the oxidative stress in these patients by eliminating the effects of AEDs. The MDA levels of untreated patients (6.81 AE 2.94 mmol/ml) were higher than those of the control group (1.75 AE 0.94 mmol/ml), with a significant P < 0.001 (Graph 1). The PC levels (0.68 AE 0.17 mg of protein/ml) of untreated patients were higher than those of the control group (0.46 AE 0.13 mg of protein/ml) with a significant P < 0.001 (Graph 2). However, the NO levels did not show any significant difference between untreated patients (47.96 AE 18.00) and the control group (55.44 AE 9.57) (P = 0.07) (Graph 3).
There were no differences between the MDA levels in untreated patients (6.81 AE 2.94 mmol/ml) versus the treated group (6.76 AE 2.82 mmol/ml) (P = 0.94) (Graph 1), the PC levels in untreated patients (0.68 AE 0.17 mg of protein/ml) and the treated group (0.71 AE 0.19 mg of protein/ml) (P = 0.63) (Graph 2) or the NO levels in untreated patients (47.96 AE 18) and the treated group (51.08 AE 15.26) (P = 0.44) (Graph 3).
Comparison between patients on monotherapy and polytherapy
No differences were found between groups 1 (monotherapy) and 2 (Polytherapy) with regard to the oxidative parameters. The oxidative levels in monotherapy versus. Polytherapy were MDA (7.28 AE 2.93 mmol/ml, monotherapy) (6.63 AE 3.25 mmol/ml, polytherapy) (P = 0.37) (Graph 1); PC (0.69 AE 0.22 mg of protein/ml, monotherapy) (0.70 AE 0.12 mg of protein/ml, polytherapy) (P = 0.89) (Graph 2); NO (49.69 AE 18.67, monotherapy) (53.25 AE 19.54, polytherapy) (P = 0.43) (Graph 3), respectively.
Comparison between individual AEDs
The MDA, PC and NO levels of patients on Carbamazepine, Phenytoin and Valproate are shown in Table 3 . ANOVA analysis did not show any differences in oxidative levels between the groups. However, there was a difference in lipid parameters; the total cholesterol, HDL and LDL levels were highest in patients taking Phenytoin and lowest in patients taking Carbamazepine. 
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Graph 2. Protein carbonylation levels in patients and the control group.
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Graph 3. Nitric oxide levels in patients and the control group. 
Discussion
This study included 100 patients with epilepsy and 100 healthy control subjects. Our study demonstrated that MDA and PC levels were significantly higher in patients with epilepsy than in the control group (P < 0.001), which is a finding that is consistent with previous studies. [23] [24] [25] However, the NO levels did not vary between the 2 groups. The brain has a high lipid content, and its oxygen consumption and oxidative metabolism make it susceptible to oxidative stress. Lipid peroxidation involves oxidative degradation of lipids. Measuring Malondialdehyde, the end product of lipid peroxidation, is a relatively easy method for estimating lipid peroxidation. 18 Protein oxidation is irreversible oxidative damage, and protein damage is considered to be a marker for severe oxidative stress. 19, 26 Nitric oxide is a free radical that is formed biologically through the oxidation of L-arginine by nitric oxide synthase. The exact role of NO in the pathophysiology of epilepsy is still unclear. Several studies have shown that NO may act as an endogenous anticonvulsant. [27] [28] [29] Although some studies have shown that NO acts as a proconvulsant, 30-32 our study did not find any difference in NO levels between the patients and control group. In our study, 75 out of the 100 patients with epilepsy were on treatment for durations of 5 AE 4 years. We report significantly high levels of MDA (P < 0.001) and PC (P < 0.001) in 75 patients when compared to those of the healthy control group, but with no difference between NO levels. Our study showed that patients who were not on AEDs also had high MDA (P < 0.001) and PC levels (P < 0.001) with no difference in NO levels when compared to the healthy control group (P < 0.07). Because we found that patients who not on AEDs also had high oxidative levels, we compared this group with patients on AEDs. We did not find any significant differences between the 2 groups with regard to MDA (P = 0.54), NO (P = 0.51) and PC levels (P = 0.373). Furthermore, we did not find any difference in oxidative parameters in patients on monotherapy and polytherapy. Altogether, we conclude that oxidative stress is present in patients with epilepsy and that AEDs do not appear to play any role. Similar results have been documented in previous studies. 23 Pentylenetetrazol (PTZ)-induced seizures in the entire cortex in rats, 4 mice hippocampus 6 and pilocarpine-induced status epilepticus in rat hippocampus. 33 These experimental studies have suggested that seizures induce oxidative stress, which is confirmed in our study as well as others. 23, 24 Recurrent seizures and prolonged seizures have been found to result in both necrosis and apoptosis of a specific area of hippocampus, CA3, in experimentally induced seizures. 34 High oxidative stress and free radical generation are possible reasons for seizure-induced apoptosis and neuronal death. Patients were also found to have high levels of cholesterol, LDL and serum alkaline phosphatase as compared to the control group. There are reports that show correlations between high LDL levels, oxidative stress and endothelial dysfunction. 35, 36 Furthermore, studies have shown that oxidative stress could be an early event in the evolution of hyperlipidemia. 37 In our study, correlation analysis was not significant between lipid parameters and oxidative levels. Hence, we can only comment that patients with epilepsy had high oxidative stress with dyslipidemia, but further studies are needed to confirm this correlation. Various studies have shown that AEDs appear to modulate oxidative stress. Studies have reported increased NO levels in patients treated with VPA. 38, 39 Patients with epilepsy treated with Phenytoin, Carbamazepine and Valproate have increased MDA levels. 23, 40, 41 In our study, patients were on Carbamazepine, Phenytoin and Valproate or Polytherapy regimens. Increased MDA and PC levels were found in patients on AEDs. There was a variation in the Cholesterol, HDL and LDL levels between individual AEDs, but there were no differences in the oxidative parameters. However, our study had a relatively small number of subjects in each group. Studies with larger sample sizes are needed to confirm these results. These results have therapeutic implications. Whether free radicals released after seizure episodes lead to further seizures or refractory epilepsy needs to be addressed. However, oxidative stress has indeed been implicated in several other diseases including epilepsy. Few studies in animal models show the effects of antioxidants in decreasing the oxidative stress. Antioxidant melatonin has been found to decrease seizure activity or delay the development of epileptiform discharges in ferric chloride induced seizure models in rodents. This phenomenon was also found to accompany decreased levels of lipid peroxidation. 38, 39 Most of the previous studies were performed on patients who were already on treatment and could not conclude that the oxidative stress is a result of epilepsy or AEDs. Some studies have compared treated and untreated patients and found no difference. 20, 38 Considering the results of these studies, including ours, the role of AEDs in increasing oxidative stress is negligible.
In conclusion, our study demonstrated that there were significantly increased levels of oxidative markers in patients with epilepsy. AEDs did not influence oxidative markers, which suggests that seizures induce oxidative stress. The mechanism of epileptogenesis is still unclear. Even with the advent of newer AEDs, a significant proportion of patients are refractory to treatment. Hence, it is important to have novel methods of therapy, which include AEDs with possible adjunctive antioxidant therapy.
This study adds information to the existing literature and necessitates further detailed research to understand the mechanism of epilepsy to promote newer modalities of disease modification.
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